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Abstract
The LEAP-MS (Lifestyle, Exercise and Activity Package for People living with Progressive Multiple Sclerosis) study has
developed an individualised supported self-management approach for physical activity for people with progressive
multiple sclerosis (MS) and severe disability. The intervention has been evaluated in a single-arm feasibility study
with embedded process evaluation. The feasibility study was due to open to recruitment during the COVID-19
2020–2021 pandemic, 1 month into the first UK-wide lockdown. We worked rapidly to implement adaptions to the
trial procedures and intervention delivery that we believe are applicable to randomised controlled trials.
Recruitment became predominantly via self-referral. Electronic consent was employed, with consent discussions
occurring over the telephone. Registration, consent, eligibility assessment and data collection as well as the
intervention (online physical activity tool) were via a secure, encrypted multi-user web-based platform for
participants, physiotherapists and researchers accessible via various hardware. Physiotherapy consultations, as well
as the process evaluation, were conducted remotely using video conferencing software or the telephone. A remote
training package for physiotherapists and site initiations was also developed and electronic site files employed.
Our adaptions are extremely topical given the COVID-19 situation, and whilst not what we had originally planned,
have enabled successful delivery of the feasibility study and are relevant to conducting randomised controlled trials
and meeting the needs of people with MS who are far more isolated than ever before.
Trial registration: ClinicalTrials.gov NCT03951181. Registered on 15 May 2019.
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Background to LEAP-MS
LEAP-MS (Lifestyle, Exercise and Activity Package for
People living with Progressive Multiple Sclerosis) aims
to develop and evaluate an individualised supported
self-management approach for physical activity with a
specific focus on people with progressive multiple
sclerosis (PwPMS) and severe disability.
Multiple sclerosis (MS) is a long-term deteriorating
condition which causes a range of symptoms like blurred
vision and problems with how people move, think and
feel affecting an estimated 107,000 people in the UK [1].
Of these it is estimated that 10–15,000 have primary
progressive MS [2] and 38,000 secondary progressive
MS [3], which are characterised by worsening of symp-
toms either independent of relapses/remissions or with
relapses. PwPMS often have higher levels of disability
than those with relapsing-remitting MS, often have high
health and social care needs, and self-report low health-
related quality of life [4, 5].
Regular physical activity is generally regarded to be an
important component of long-term management of MS
[6, 7]. Physical activity may have a positive impact on MS
symptoms, including mobility, cognition and fatigue, and
have important physical, psychological and social benefits
[8, 9]. Various interventions are reported in the literature,
ranging from group interventions to digital versatile disk
(DVD) and web-based interventions [10–14] but most re-
search to date has focussed on patients who are walking
and evidence in progressive MS is inconclusive [8, 15, 16].
Despite the possible benefits, we know that people
with MS want to be physically active [6, 17]. In particu-
lar, those who are more disabled find it hard to start and
maintain activity, and often do not receive any or
enough support [18]. Pro-active approaches to support-
ing physical activity (often called self-management inter-
ventions), that empower individuals to continue to be
physically active independently following health profes-
sional input are therefore urgently needed for this group
of people with MS [19].
In MS there is an additional need for health professionals
to really understand the condition and have the knowledge
and skills in relation to self-management of physical activity
[19]. As supporting people to self-manage their physical ac-
tivity might require physiotherapists to work differently, we
need to know more about the specific training they need to
provide the right sort of support. We also need to know
more about how physical activity interventions can be suc-
cessfully personalised to meet the needs of individuals with
PwPMS, and what the associated costs/challenges are to
the use of this approach in practice.
Phase 1: qualitative interview study
In phase 1 of the LEAP-MS study, we collected informa-
tion about the barriers to and facilitators of physical
activity that PwPMS experience, their current levels and
type of physical activity and their perceptions of the role
physical activity plays in managing MS symptoms from
both them and their families—or people that support
them. This provided us with important information
about why physical activity might be important for
PwPMS, the challenges they face in doing physical activ-
ity or accessing it, and ways which they have found to
overcome any barriers. We also collected information
from physiotherapists about their understanding of self-
management and their needs for training about using
self-management approaches with PwPMS.
Phase 2: intervention development and feasibility testing
We used this information gathered in Phase 1 to work
with PwPMS and physiotherapists to co-design the
LEAP-MS personalised intervention to facilitate on-
going physical activity for people with PwPMS. The out-
comes achieved through the collaboration have exceeded
expectations through the co-production of an online
education and activity platform, a patient-led approach
to consultations, an online hub providing resources for
clinicians delivering research protocols and a novel
online-only evaluation method (paperless) for clinical
evaluation of the co-produced interventions.
The intervention is made up of:
 A multi-user web-based online physical activity tool
 Up to six physiotherapy consultations (coaching
sessions)
 A training package for physiotherapists about self-
management with PwPMS
Further details of the intervention development
are published separately [20].
We sought to evaluate the feasibility and acceptability
of the intervention and trial procedures in a single-arm
feasibility study with embedded process evaluation [21].
The study was due to open to recruitment in April 2020,
1 month into the first UK wide lockdown during the
COVID-19 2020–2021 pandemic [22].
Original feasibility study protocol (pre-COVID-19
pandemic)
The study had ethical approval (Wales REC 6, reference
19/WA/0195) and sought R&D approval from three NHS
Health Boards in Wales to recruit 21 participants via three
recruitment routes, namely (1) a MS research database
hosted in the NHS; (2) referral from NHS outpatient
physiotherapy services; (3) self-referral from within Health
Boards. Recruitment routes 1 and 3 required the potential
participant to register their interest in the study via the
LEAP-MS website, self-complete an online consent form,
initial eligibility screen and baseline self-completion
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measures. For participants recruited via route 2 in physio-
therapy outpatient clinics, written informed consent, eligi-
bility assessment and baseline measures would be
undertaken at the clinic in person. In all cases, consent
and eligibility would be reconfirmed at the initial home-
based (face-face) coaching session by a physiotherapist,
who had received tailored intervention and study proced-
ure training. Eligible patients had either primary or sec-
ondary progressive multiple sclerosis (as defined by the
Lublin classification) [23], were aged 18 or over and had
an Expanded Disability Status Scale (EDSS) score [24] be-
tween six (able to walk 100m with an aid) and eight (re-
stricted to bed, chair or wheelchair but may be out of bed
much of the day). Participants had capacity to consent to
study participation on their own behalf and had access to
mobile, wireless or wired internet connection at home.
Any individuals with relapsing-remitting or non-
progressive MS, were unable to understand written and
spoken English, or were pregnant or planning a pregnancy
were excluded.
Following the initial coaching session, the participants
would have been given access to the online intervention
for an initial 3-month period. During this period partici-
pants would be able to request up to five further home-
based physiotherapy coaching sessions, after which the
LEAP-MS platform without physiotherapy support
would be available to participants for a further 3 months.
Follow-up was scheduled for 3-months and 9-months
post-baseline. The following outcome measures were to
be self-completed by the participants and collected using
the online study platform at baseline and both follow-up
timepoints:
 Modified form of the Fatigue Impact Scale (MFIS)
[25] to assess fatigue in terms of physical, cognitive,
and psychosocial functioning;
 Multiple Sclerosis Impact Scale (MSIS-29) to
measure the physical and psychological impact of
MS from the patient’s perspective [26];
 EQ-5D-5 L to provide an indication of health-related
quality of life [27];
 Oxford Participation and Activities Questionnaire
(OxPAQ) to assess the impact of ill-health on par-
ticipation, activities and autonomy [28];
 University of Washington 6-item short form self-
efficacy scale (UW-SES-SF) (MS specific) to indicate
self-efficacy [29];
 Modified Patients’ Global Impression of Change (PGIC)
[30] at 3 months and 9 months follow-up only.
Semi-structured interviews were going to be con-
ducted in person with participants 3 months after base-
line. Consenting intervention physiotherapists were also
going to be interviewed in person once all their
participants had received the intervention for the initial
3-month period. Usage of the LEAP-MS platform was
going to be tracked during the 6-month intervention
period. Intervention physiotherapy notes were intended
to be completed on paper, as was the eligibility assess-
ment undertaken by the physiotherapist and any safety
reporting case report forms. The intervention coaching
sessions were going to be observed in person by the
study’s qualitative researcher. Costs associated with
intervention delivery (therapist travel and contact time)
were also going to be recorded by the physiotherapists.
COVID-19 pandemic restrictions and implications
The COVID-19 2020/2021 pandemic [22] and the
resulting imposed restrictions [31, 32] meant that many
of the intended study procedures described above were
not feasible. Recruitment into clinical trials and studies
that were not related to COVID-19 ceased within the
NHS [33]. NHS staff who had been trained to deliver the
intervention had to be redeployed to hospital wards or
in community positions and were unable to deliver the
intervention as planned [34, 35]. Exercise and social
groups were disbanded, and gyms and leisure centres
closed [31, 32]. Social distancing rules prevented face-
face visits being conducted. Obtaining paper-based writ-
ten informed consent and paper-based data collection
also became problematic.
Revised feasibility study protocol
Given the impending start of recruitment we worked
rapidly to implement amendments and succeeded in se-
curing a 6-month no-cost extension from the funder
(MS Society). The following amendments to the feasibil-
ity study protocol were classed as non-substantial
amendments under the guidance issued by the Health
Research Authority [36] and the revised protocol was
submitted for publication (currently under review) [21].
Research sites
As the intended research sites were unable to open to
recruitment due to staff redeployment and revised NHS
priorities, non-NHS research sites were set up. Physio-
therapists were utilised from within the project team to
deliver the intervention, so not to draw resources from
the NHS. NHS research sites were able to open to re-
cruitment once recruitment to non-COVID-19 clinical
trials and studies resumed.
Training
Time was invested in developing a bespoke LEAP-MS
physiotherapy training package that focused on the
provision of self-management support to participants,
the use of technology in consultations, updates on phys-
ical activity and exercise guidelines for long-term
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neurological conditions, what to expect when using the
LEAP platform along with potential challenges and solu-
tions. The initial training package was developed
through a two-day face-face interactive workshop under-
pinned by Bridges Self-Management principles and de-
livered by Bridges Social Enterprise (http://www.
bridgesselfmanagement.org.uk/), in which ten physio-
therapists participated in prior to the COVID-19 pan-
demic. The workshop was video recorded and utilised as
part of the final online training package. Further re-
sources to help structure remote interactions (https://
www.bridgesselfmanagement.org.uk/covid-19-resources/
) were made available to standardise coaching interac-
tions regardless of mode of delivery. Site initiation train-
ing in study procedures was delivered remotely via
Zoom [37], recorded and made available as part of the
online training package. User guides on study processes
were also developed. Physiotherapists were given access
to conversation-based scripts to guide coaching conver-
sations and had the opportunity to practice coaching
conversations and receive peer review. All resources
were accessed via the LEAP-MS multimedia online
learning resource.
Recruitment, e-consent and eligibility assessment
Physiotherapists who attended the intervention training
and site initiation were emailed the physiotherapist infor-
mation sheet and a link to the online consent form. They
were asked to complete an informed consent form using
Cardi f f onl ine survey software (https : //cardi f f .
onlinesurveys.ac.uk/), save a local copy of the consent
form and email it to the LEAP-MS email address. A copy
was also saved in the electronic investigator site file.
MS Society endorsed communication channels were
utilised as an additional recruitment pathway. Potential
participants within the South Wales region were emailed
by the MS register. The MS research database was also
used as initially planned, from which potential partici-
pants were sent a letter. Both the email and letter were
accompanied by the patient information sheet. Potential
participants then registered their interest using the on-
line study platform generating a unique login, providing
their contact details and self-completing a brief online
eligibility screen. An automated email was sent to
LEAP-MS email account to notify the study team of the
registration. After which, the participant was contacted
by telephone by the central study team, given the oppor-
tunity to ask questions and have their responses to the
initial eligibility screen reviewed. If deemed to still be eli-
gible, the electronic consent form was released to the
potential participant’s LEAP-MS account through the
online platform and they were also emailed to request
they login using their registered login and complete the
online consent form and the baseline measures. The e-
consent form consisted of declarations with yes/no tick
boxes, typed name, typed date and date of birth, and an
automatic date/time stamp generated as part of the audit
trail upon saving the form. Eligibility was reconfirmed
by the intervention physiotherapist during the initial
online (Zoom) coaching session and recorded by the
physiotherapist on an electronic case report form
accessed from the online platform.
Intervention delivery
Virtual physiotherapy consultations using web conferen-
cing software (Zoom [37]) or telephone were allowed in
addition to, or in replace of, face-face consultations. Par-
ticipants were offered a practice Zoom session with the
central study team prior to the first physiotherapist con-
sultation (coaching session) to facilitate familiarisation
with the technology. We also tried to balance the assign-
ment of physiotherapists to cover different environments
(NHS based and University based, different levels of
training and different referral routes). All risk assess-
ment documentation was revised to address remote
intervention delivery.
Data collection and management
The follow-up period was reduced from 9-months to 6-
months and the economic evaluation was removed to
streamline data collection.
We developed a secure, encrypted multi-user web-
based platform for participants, physiotherapists and re-
searchers accessible via desktop computers, laptops, tab-
lets or smart phones. Participants were able to use the
platform to register, complete eligibility forms, consent,
baseline and follow-up measures as well as to access the
intervention. The physiotherapist-completed case report
forms were incorporated into the online platform, with
the added functionality of being able to download the
therapy notes to facilitate incorporation into the pa-
tients’ NHS medical records. Participants, physiothera-
pists and administrators all had different access and
editing level permissions. As participants entered their
own data most of the data could not be queried; to limit
errors and ensure quality data inbuilt database valida-
tions were used including using input masks, restricted
data formats and mandatory data fields. Effort was made
to make the platform visually appealing, easy to navigate
and allowed one measure/case report form to be com-
pleted and saved at a time. The platform was also used
by the study team to evaluate participant engagement
with the intervention and to manage study data.
The process evaluation also had to be undertaken re-
motely; recorded Zoom coaching sessions were used for
the observations and the qualitative interviews were con-
ducted over Zoom or telephone.
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The use of an electronic study master file and elec-
tronic investigator site files were also employed. Micro-
soft One Drive and password protected files on secure
shared drives on University servers were used.
Discussion: efficiencies and challenges
Efficiencies have been achieved in multiple areas relevant
to the delivery of the LEAP-MS study. Most notably
flexibility in intervention delivery reduced burden on the
NHS and ensured that we were able to successfully re-
cruit, consent, deliver assessments and evaluate out-
comes in a group of PwPMS who were increasingly
isolated given the COVID-19 lockdown restrictions. In
our view, the availability of an online training package
and the conduct of remote site initiation was key to the
success we observed in rapidly opening sites. Some of
the physiotherapists who were relatively new to research
required additional assistance and support when under-
taking the study processes. This may not have been the
case had training been delivered face-face. Whilst re-
mote training may reduce site buy-in and rapport due to
the limited personal contact, we would recommend that
the mode of delivering the training and site initiations
should be considered on a study-by-study basis.
Advertising the study to potential participants via MS
Society communication channels proved highly efficient
providing greater reach as expressions of interest be-
came independent of Health Board and gave scope for
increased generalisability. It was however limited in that
the study team were not able to ensure clinical confirm-
ation of the EDSS score. This was dealt with through an
additional eligibility screen conducted by the central
study team followed by a further physiotherapist eligibil-
ity assessment at the first physiotherapy consultation.
We used an electronic trial master file and site files
and developed a system to enable the electronic registra-
tion and consent process. A separate study visit was thus
not required to obtain informed consent thereby redu-
cing both staff and participant burden. We found that
approximately a third of participants required explicit
instructions and a link to the website/consent form area,
before they were successfully able to access the website
and complete the online consent form. This may have
been compounded by the patient population as impaired
cognitive and memory function are common symptoms
of MS; however, we would recommend building an auto-
mated email function into the online platform to notify
participants when the consent form is released to them
for completion.
The LEAP-MS database acts as the source consent
documentation and will be retained for the required ar-
chiving period in line the requirements for archiving the
electronic data set, and thereby also being accessible in
case of a statutory inspection(s). The LEAP-MS patient
information sheet explained that University staff would
have access to their data and the completed consent
form, and explicit consent was sought for this as one of
the statements on the consent form. A copy of the com-
pleted consent form was downloaded and saved in the
electronic investigator site file for retention by the site.
The participant had access to their completed consent
form through the online platform. We are considering
how to enable the participant to have long-term access
to the completed consent form. The intention for future
iterations of the platform is to enable participants to
download, save and/or print their completed consent
form. For this study, we intend to download and post
the completed consent form to the participant’s home so
they have a copy once access to the platform is removed.
The e-consent process and system used in LEAP-MS
exceeds the ethical and legal requirements for e-consent
recommended for ‘other types of research’ as described
in the joint statement on seeking consent by electronic
methods [38]; it also fulfils the e-consent requirements
for type A Clinical Trials of Investigational Medicinal
Products (CTIMPs) [39]. For higher risk trials, the verifi-
cation process could be strengthened by checking identi-
fication (e.g. passport or driving licence) as part of the
video conference call. We believe there is potential to
utilise this approach to collect baseline data from the
participant prior to a study visit where consent can be
confirmed in person prior to the administration of any
Investigation Medicinal Product or higher-risk trial
intervention.
Due to the COVID-19 pandemic there has been an ex-
pedited move towards telemedicine and remotely deliv-
ered rehabilitation [40, 41]. This trend looks set to
continue and we are likely to see many changes in the
delivery of rehabilitation moving forward [42, 43]. Most
trials that are delivered remotely still include face-face
components [44, 45]. The LEAP-MS intervention was
originally designed to have face-face coaching sessions
alongside a web-based platform. The existing platform
facilitated modifications to remote delivery only. Crucial
to moving to remote delivery were meeting the add-
itional training needs of both the physiotherapists and
the participants, as well as considering how to conduct
the fidelity evaluation. Physiotherapists and participants
required some level of digital literacy to take part in
LEAP-MS. Physiotherapists required practice sessions
using both the online platform and the video conferen-
cing software, particularly when using them simultan-
eously, and for some participants, LEAP-MS was their
first experience of using online conferencing and an on-
line resource of any type. We would recommend time
for this is built into the study timelines.
Technical issues were experienced in a number of con-
sultations relating to internet connectivity, sound and
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video quality as well as user capability and confidence;
two participants ended up having their first consultation
over the telephone, one of these participants also had
their second consultation over the phone. Attend Any-
where [46] was initially considered for the video confer-
encing software as it was rising in popularity within the
NHS. Microsoft Teams [47] was also considered, how-
ever, we decided to use Zoom due to its ease of use (par-
ticipant interface), recording ability (required for the
process evaluation), and that the sponsor had a Zoom
business account (additional confidence in data security).
All the NHS intervention physiotherapists were given a
University email account to enable them to use Zoom
for their LEAP-MS consultations. Consideration of
which video conferencing software to use in any future
trial(s) will be required to maximise the benefit and min-
imise inconvenience.
Participants experienced a shorter waiting time (mean
of 3 weeks) for their initial physiotherapy appointment
compared to typical home visit waiting times of up to
8 weeks [48]. This was in part due to the study using
both NHS and non-NHS physiotherapists but also be-
cause the physiotherapist’s time was maximised as travel
to the participant’s home was not required and initial re-
search activities such as expressions of interest, discuss-
ing and obtaining informed consent, and the initial
eligibility screen had already been conducted prior to
the first physiotherapy consultation.
The online intervention platform has been future-
proofed in that recommendations for activities not
allowed due to COVID-19 pandemic social restrictions
have been blocked but were included in the build so that
access can be easily allowed in future. LEAP-MS has also
featured in the NIHR remote delivery guidance as an ex-
ample of remote delivery of complex interventions [49].
Although this study is a single-arm feasibility study,
the database has been developed so that it can be effi-
ciently repurposed for a main randomised controlled
trial. The participant self-report outcome measures used
in LEAP-MS were intended to be collected remotely
prior to the COVID-19 pandemic using the online plat-
form. The database had in-built validations to ensure
high-quality data and efficient data management. Lim-
ited data querying and data cleaning could be conducted
as participants’ self-completed many of the measures.
Data management tasks focused primarily on prompting
participants to complete the forms. Initial prompts were
conducted by email 2-weeks and 1-week before follow-
ups were due, however, the number of completed forms
improved when the email prompts were accompanied by
telephone calls. This may in part be due to the patient
population but could also be due to external factors
effecting participants’ mood, such as the follow-ups co-
inciding with increased COVID-19 related social
restrictions and the local and national lockdowns of au-
tumn and winter 2020 [31, 32].
Some technical issues were experienced with the data-
base, mainly that the data collection forms were locked
part way through two participants completing their base-
line measures, and three participants were able to
complete their 6-month follow-up prior to their
intended follow-up window. These errors were rectified
as soon as the central team became aware. Although
standard database testing was employed, the scheduling
of access to forms was not initially tested, and this ex-
perience highlights the necessity for thorough testing
prior to database release, especially when participants
are entering their data themselves.
The physiotherapist-completed case report forms were
incorporated into the online platform due to the
COVID-19 implications. A benefit of this, in addition to
reduced data entry and reduced printing and stationary
costs, was the added functionality of being able to down-
load the therapy notes. Although this function was not
used during this study, it will facilitate incorporation
into the patients NHS medical records in the future.
Conclusion
In LEAP-MS, we have developed an entirely novel ap-
proach to remote participant enrolment, consent and as-
sessment as well as a more comprehensive, interactive
and adaptable intervention than was originally planned,
which can be delivered remotely. Both of which are very
topical given the COVID-19 situation and our evalu-
ation, whilst not what we had originally planned, is
highly relevant to meeting the needs of people with MS
who are far more isolated than ever before. Pending our
evaluation in this single-arm study, we propose a follow-
on randomised feasibility trial (if major modifications
are indicated during our evaluation) or a plan to pro-
gress to a full effectiveness evaluation with internal pilot
to assess willingness to be randomised should only
minor modifications be required.
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